RxSight price target raised to $72 from $61 at BTIG

BTIG raised the firm’s price target on RxSight to $72 from $61 and keeps a Buy rating on the shares. The company’s Q1 results were strong, with “impressive” utilization metrics and gross margins that jumped to a new high of 70.1%, the analyst tells investors in a research note. RxSight’s guidance raise is also achievable based on the modest increase in utilization required for the remainder of the year, the firm added.